Pesquisa
Educação
Entrar
PT
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
Department of Medicine,
Helen Diller Family Comprehensive Cancer Center,
Department of Cellular and Molecular Pharmacology
Trever G. Bivona has not added Biography.
If you are Trever G. Bivona and would like to personalize this page please email our Author Liaison for assistance.
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
Nature cell biology 09, 2018 | Pubmed ID: 30104724
Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway.
Science (New York, N.Y.) 08, 2018 | Pubmed ID: 30166458
Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.
Cancer research 02, 2019 | Pubmed ID: 30538120
Immunohistochemistry to Study YAP in Human Tissue Samples.
Methods in molecular biology (Clifton, N.J.) , 2019 | Pubmed ID: 30565127
Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology.
Trends in molecular medicine 03, 2019 | Pubmed ID: 30686761
Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.
Current oncology reports 02, 2019 | Pubmed ID: 30806814
Polytherapy and Targeted Cancer Drug Resistance.
Trends in cancer 03, 2019 | Pubmed ID: 30898264
Dampening oncogenic RAS signaling.
Science (New York, N.Y.) 03, 2019 | Pubmed ID: 30898918
Engineering Multidimensional Evolutionary Forces to Combat Cancer.
Cancer discovery 05, 2019 | Pubmed ID: 30992280
Targeting Oncogenic BRAF: Past, Present, and Future.
Cancers Aug, 2019 | Pubmed ID: 31426419
Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.
Cell reports 08, 2019 | Pubmed ID: 31461649
Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale.
Cancers Sep, 2019 | Pubmed ID: 31533235
Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 01, 2020 | Pubmed ID: 31548343
Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma.
Nature communications 07, 2020 | Pubmed ID: 32699215
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
Cell 09, 2020 | Pubmed ID: 32822576
Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.
Current opinion in chemical biology 06, 2021 | Pubmed ID: 33418513
Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts.
Science (New York, N.Y.) 02, 2021 | Pubmed ID: 33479121
Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules.
Cell May, 2021 | Pubmed ID: 33848463
Stepwise evolution of therapy resistance in AML.
Cancer cell Jul, 2021 | Pubmed ID: 34171262
Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote virus detection and cancer.
Cell reports Aug, 2021 | Pubmed ID: 34348154
University of California, San Francisco
Dora Barbosa Rabago1,2,3,
Collin M. Blakely1,2,
Franziska Haderk1,2,3,
Trever G. Bivona1,2,3
1Department of Medicine, University of California, San Francisco,
2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco,
3Department of Cellular and Molecular Pharmacology, University of California, San Francisco
Privacidade
Termos de uso
Políticas
Entre em contato
recomende à biblioteca
Newsletter
JoVE Journal
Coleções de métodos
JoVE Encyclopedia of Experiments
Arquivo
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Centro de Recursos para Docentes
Autores
Bibliotecários
Acesso
SOBRE A JoVE
Copyright © 2024 MyJoVE Corporation. Todos os direitos reservados